Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-27-2015 | Award Amount: 4.90M | Year: 2016
Silicon photonics is expected to leverage-off many of the advances made in CMOS electronics. International R&D efforts in this field have so far been mainly focused on the silicon-on-insulator (SOI) photonic integrated circuit (PIC) technology platform because it is predestined for datacom, high-performance computing and telecom applications. However, SOI based integrated optical waveguides cannot be used for the VIS/NIR <1.1m wavelength region, which is important for life sciences and health related applications and, thus, offers a huge potential for PIC technology. To this end, a novel CMOS compatible low-loss silicon nitride waveguide based PIC technology platform will be developed in OCTCHIP and directly applied to the a strong business case in the field of optical coherence tomography (OCT) for ophthalmology. OCT is a revolutionizing in-vivo 3D imaging technique for non-invasive optical biopsy addressing medical needs with early diagnosis and reduction of healthcare cost. OCT has proven its value primarily in ophthalmology and cardiology but recently also in a variety of other medical fields. However, wide adoption has not taken place due to size and cost limitations as well as non-existence of miniaturized devices. The PIC technology developed in OCTCHIP will make a new generation of OCT systems possible with step-changes in size and cost beyond state-of-the-art. The monolithic integration of silicon nitride optical waveguides, silicon photodiodes and electronics combined with the hybrid integration of a III-V laser source will enable a compact, low-cost and maintenance free solution. OCTCHIP will contribute to radically transform OCT towards widespread adoption in point-of-care diagnostics for the early diagnosis of retinal pathologies, which are leading causes for blindness. The endeavor is strongly driven by company partners with strong expertise in the fields of silicon foundry process technology, miniaturized laser sources, and OCT system integration.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.2-1 | Award Amount: 7.83M | Year: 2014
Background: Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptable in relation to the lethal outcome of HH although massively reducing quality of life and also life expectancy. Aims and objectives: In order to significantly improve therapy of this awful disorder, we propose to develop a simultaneous imaging/therapy platform allowing diagnostic imaging as well as image guided surgical, photodynamic or radiopeptide therapy to selectively resect/destroy diseased beta cells. This platform will enable delivery of patient-individual tailored therapy, increasing cure rate while significantly reducing or even avoiding side effects. The platform will integrate information from pre-clinical imaging for optimal therapy planning with intra-operative imaging for image guided surgery. By implementation of extended field optical coherence tomography, information on a histopathological level will allow increased precision of therapy. Highly innovative photodynamic therapy will enable selective (endoscopic) destruction of diseased beta cells without resection of pancreatic tissue. Outcome: Our highly-innovative integrated imaging/therapy (theranostic) platform will allow diagnosis and monitoring of disease, support and guide therapeutic intervention, predict outcome of intervention and individual prognosis. This technology will massively improve therapy, especially in infants, by improving cure rates while significantly reducing morbidity for improved quality of life and increased life expectancy. We will contribute to the goals of the International Rare Diseases Research Consortium (IRDiRC): 200 new therapies.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2011.3.5 | Award Amount: 13.40M | Year: 2012
Biophotonics offers low-cost, non-invasive, accurate, rapid alternatives to conventional diagnostic methods and has the potential to address medical needs with early detection and to reduce the cost of healthcare. FAMOS will develop a new generation of light sources with step-changes in performance beyond the state-of-the-art to radically transform biophotonic technologies for point-of-care diagnosis and functional imaging. This will enable optical diagnostics with superior sensi-tivity, specificity, reliability and clinical utility at reduced cost, heralding an imaging renaissance in Europe.FAMOS addresses optical imaging from molecular over (sub)cellular to individual organs, with no gap in the arsenal of diagnostic tools for medical end-users. The world-class multidisciplinary FA-MOS team of 7 leading academic institutions and 10 top SMEs has unique complementary knowledge of optical coherence tomography, adaptive optics, photoacoustic tomography, coherent anti-stokes Raman scattering, multiphoton tomography as well as swept-source, diode-pumped ultrafast and tuneable nanosecond pulse lasers. Combinations of some techniques will offer multi-modal solutions to diagnostic needs that will exploit and enhance the benefits of each modality. FAMOS technologies have wide applicability, but our specific focus is on diagnosis in ophthalmol-ogy and oncology. Partnerships with leading innovative clinical users will enable preclinical evalua-tion.The objectives of FAMOS are:\tDevelop new light sources with a step-change in performance (2-3 times more compact and up to 3-4 times cheaper diode pumped Ti:sapphire, 4-10 times faster swept sources and tuneable nanosecond pulse sources)\tIntegrate these with optical imaging for a step-change in diagnosis (2-5 times better resolution cellular retinal imaging with more than 10 times larger field of view, up to 10 times enhanced penetration single source subcellular morphologic imaging, increased selectivity of intrinsic mo-lecular sensing as well as several frames per second deep tissue functional tomography\tPerform preclinical studies to demonstrate novel or improved ophthalmic and skin cancer diag-nosis establishing novel biomarkers (melanocyte shape, NADPH, melanin concentration, Hb/HbO2 as well as lipid, water and DNA/RNA concentration)\tEnable exceptional commercial opportunities for SMEs\tProvide state-of-the-art academic training
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2013.3.3 | Award Amount: 4.67M | Year: 2013
Optical coherence tomography (OCT) is an emerging optical diagnosis that enables in vivo tomographic visualization for non-invasive optical biopsy. OCT has proven its value primarily in ophthalmology, but recently also in dermatology. However, wide adoption has not taken place due to size and cost limitations as well as non-existence of handheld devices.\nHence BIOPSYPEN will develop a new OCT generation with step-changes in size and cost beyond state-of-the-art to radically transform OCT instrumentation for handheld point-of-care diagnosis. In contrast to conventional approaches, BIOPSYPENs OCT is based on integrated optics, more precisely on hybrid integration of silicon photonics with III-V sources, enabling a significantly smaller, low-cost, compact and maintenance free alternative.\nBIOPSYPEN will target complementary research to develop an unprecedented compact (pencil-like), reliable, low-cost, battery-operated, wireless handheld OCT device in combination with an embedded system based external console to receive two-and three-dimensional tomograms for instantaneous post processing and visualization as well as immediate diagnosis.\nBIOPSYPEN will contribute to a significantly wider adoption of OCT in real clinical point of care settings. Early diagnosis of skin cancer and inflammatory skin diseases are envisaged. Skin cancer will be used as a surrogate for other epithelial cancers, e.g. oral, gynaecologic or gastrointestinal cancer. Partnerships with leading innovative clinical users will enable preclinical evaluation.\nThrough the use of integrated optics in combination with complementary cutting-edge technologies, BIOPSYPEN will dramatically reduce cost and size (both at least by one order of magnitude) of currently available OCT commercial systems. It will also eliminate instrumentation maintenance requirements and will reduce training and healthcare costs, paving the way to revolutionize diagnosis for general medicine and primary care.
Matuschek N.,EXALOS AG |
Duelk M.,EXALOS AG
IEEE Journal on Selected Topics in Quantum Electronics | Year: 2013
The availability of analytical models and numerical simulation tools is inevitable for the development and optimization of broadband high-power superluminescent light-emitting diodes (SLEDs) and its applications. In this paper, various theoretical aspects of SLEDs are discussed, which are important for the successful design of new devices with superior performance. We study the suppression of residual facet reflections as well as the importance of a careful vertical waveguide design. Furthermore, a simple analytical model for the L-I characteristics of SLEDs is developed that is based on a power law with an exponent that is dependent on the chip length. The theoretical model is verified by a comparison with experimental results of a broadband SLED operating in the wavelength region around 1300 nm. It is shown that the model can be also used to extract important simulation parameters from measured L-I characteristics. Finally, results are presented for an improved high-performance SLED structure in the same wavelength region with output powers of more than 50 mW and a 10-dB spectral bandwidth beyond 100 nm. © 1995-2012 IEEE.
Zang Z.,Kyushu University |
Mukai K.,Kyushu University |
Navaretti P.,EXALOS AG |
Duelk M.,EXALOS AG |
And 2 more authors.
Applied Physics Letters | Year: 2012
Low thermal resistance of high power superluminescent diodes (SLEDs) by using active multi-mode interferometer (active-MMI) is presented in this paper. The active layer temperature evaluation demonstrates that the power saturation mechanism in active-MMI SLED is heat for the first time. Low thermal resistance of 4.83 K/W in active-MMI SLEDs leads to a high power of 115 mW. Moreover, the effect of the active area size on the output power is demonstrated both experimentally and theoretically. Good agreement between the theoretical and experimental results indicates that active-MMI configuration is a new design in support of efficient heat dissipation and thermal resistance reduction for SLEDs. © 2012 American Institute of Physics.
Exalos Ag | Date: 2010-01-22
A swept wavelength light source is provided, the light source includes a semiconductor gain device operable to provide amplification, an optical retarding device, the retarding device having a block of material, a beam path with a well-defined beam path length being defined for light within the block of material produced by the gain device, a wavelength selector, and the gain device, the retarding device and wavelength selector being mutually arranged on the base so that a resonator is established for light portions emitted by the gain device and selected by wavelength selector; this does not exclude the presence of further elements contributing to the resonator, such as additional mirrors (including resonator end mirrors), lenses, polarization selective elements, other passive optical components, etc.; wherein the beam path in the retarding device is a part of a beam path of the resonator.
Exalos Ag | Date: 2013-01-11
In accordance with the invention, a display apparatus comprising a light source is provided, said light source comprising at least one superluminescent light emitting diode (SLED), the apparatus further comprising at least one light modulating device arranged in a beam path of a light beam emitted by said light source and operable to emit influenced light upon incidence of said light beam, the light modulating device being operatively connected to an electronic control, the display apparatus further comprising a projection optics arranged in a beam path of said influenced light.
Exalos Ag | Date: 2013-12-06
An optical module includes a light source. The light source can be a swept wavelength light source, and optical module includes a wavemeter. The wavemeter includes a wavemeter tap capable of directing a wavemeter portion of light produced by the light source away from a main beam, a wavelength selective filter arranged to receive the wavemeter portion, a first wavemeter detector arranged to measure a transmitted radiation intensity of radiation transmitted through the filter, and a second wavemeter detector arranged to measure a non-transmitted radiation intensity of radiation not transmitted through but reflected by the filter. In addition, an optical coherence tomography apparatus includes the optical module.
Exalos Ag | Date: 2013-01-09
An external cavity semiconductor laser light source comprises includes a semiconductor gain device operable to provide light amplification; a wavelength selection element including a diffraction grating; and light re-directors. The gain device, light re-directors and grating are arranged so that an optical resonator is established for light portions emitted by the gain device and diffracted by the diffraction grating. The resonator is an external cavity laser resonator. The light source is capable of varying an angle of incidence of radiation circulating in the resonator onto wavelength selection element to select a resonator radiation wavelength dependent on the angle of incidence.